Caplin Point's sterile injectable site in Chennai gets two USFDA observations
New Delhi: Caplin Point Laboratories Monday said the US health regulator has made two observations after completion of inspection at its subsidiary's sterile injectable site in Tamil Nadu.
The US Food and Drug Administration (USFDA) has completed inspection of Caplin Steriles Ltd's site at Gummidipoondi in Tamil Nadu, between June 6-14, 2019.
At the end of this scheduled Good Manufacturing Practice (GMP) inspection, there were only two observations, Caplin Point Laboratories said in a BSE filing.
Read Also: Caplin Point gets 2 USFDA observations for sterile injectable site in Chennai
Caplin Point Laboratories said it believes these observations are procedural in nature and corrective and "preventive actions for these observations will be presented to the USFDA shortly".
"The observations made did not repeat observations or related to data integrity. This was the third USFDA audit at the plant since 2016," the company added.
Caplin Point Laboratories Chairman C C Paarthipan said: "our primary focus is to ensure the integrity and maintain transparency in our quality systems, and we're pleased with the result of yet another successful audit."
Read Also: Caplin steriles signs license, supply agreement with Baxter for injectable portfolio
Shares of Caplin Point Laboratories were trading 0.64 per cent lower at Rs 420 apiece on BSE.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at email@example.com. Check out more about our bureau/team here